Stryker

News

Reuters - 4 weeks ago

Teleflex beats quarterly profit estimates on robust medical devices demand

Teleflex beats quarterly profit estimates on robust medical devices demand Oct 31 (Reuters) - Surgical equipment maker Teleflex TFX.N reported a better-than-expected profit for the third quarter on Thursday, helped by strong demand for its medical devices. Robust demand for non-urgent procedures, especially among older adults, have kept investor expectations heightened around the performance of medical device makers over the past year.

Reuters - 4 weeks ago

Implant maker Zimmer Biomet lowers full-year profit forecast

Implant maker Zimmer Biomet lowers full-year profit forecast Oct 30 (Reuters) - Hip implant maker Zimmer Biomet ZBH.N lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was managing some of the company's operations. Zimmer Biomet said in September it had to replace its enterprise resource planning (ERP) system due to "usual glitches".

Reuters - 4 weeks ago

U.S. Agilon Health, Alphabet, Crocs

U.S. RESEARCH ROUNDUP-Agilon Health, Alphabet, Crocs Oct 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Agilon Health, Alphabet and Crocs, on Wednesday. HIGHLIGHTS * Agilon Health Inc AGL.N : Citigroup cuts to sell from neutral * Alphabet Inc GOOGL.O : Seaport Research Partners raises to buy from neutral * Crocs Inc CROX.O : Raymond James cuts to market perform from outperform * Leggett & Platt Inc LEG.N : Piper

Reuters - 4 weeks ago

Stryker Corp reports results for the quarter ended in September 30 - Earnings Summary

Stryker Corp reports results for the quarter ended in September 30 - Earnings Summary Stryker Corp SYK.N reported quarterly adjusted earnings of $2.87 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $2.46. The mean expectation of twenty eight analysts for the quarter was for earnings of $2.77 per share.

Reuters - 4 weeks ago

Stryker raises annual profit forecast on robust demand for medical, surgical devices

Stryker raises annual profit forecast on robust demand for medical, surgical devices Oct 29(Reuters) - Stryker Corp SYK.N slightly raised its annual profit forecast on Tuesday, banking on strong demand for its medical and surgical devices and healthy procedural volumes. Shares of the Kalamazoo, Michigan-based company rose 3.3% to $367, in after-market hours.

Reuters - 4 weeks ago

Stryker Q3 Adjusted EPS USD 2.87 Vs. IBES Estimate USD 2.77

BRIEF-Stryker Q3 Adjusted EPS USD 2.87 Vs. IBES Estimate USD 2.77 Oct 29 (Reuters) - Stryker Q3 adjusted gross margin 64.5%. Q3 adjusted EBIT margin 24.7% Q3 adjusted net income USD 1,100 million vs. IBES estimate USD 1,070 million Q3 EPS USD 2.16 Q3 revenue USD 5,500 million vs. IBES estimate USD 5,373 million Q3 net income USD 834 million outlook

Reuters - 4 weeks ago

Election-agitated Treasuries meet megacap earnings

MORNING BID AMERICAS-Election-agitated Treasuries meet megacap earnings A look at the day ahead in U.S. and global markets from Mike Dolan Even as public borrowing estimates were shaved on Monday, U.S. Treasury yields continue to probe three-month highs as markets lean toward a win for Donald Trump in next week's election and a possible clean sweep in Congress for his Republican party.

Reuters - 1 month ago

Hurricane-related IV fluid shortage could hurt medical device makers (Oct 17)

CORRECTED-Hurricane-related IV fluid shortage could hurt medical device makers (Oct 17) Corrects paragraph 3 in Oct. 17 story to say Baxter expects to meet 90% to 100% of allocation for certain products, not all products. The story was previously refiled to correct dateline By Manas Mishra and Christy Santhosh Oct 17 (Reuters) - A shortage of intravenous (IV) saline fluids due to Hurricane Helene is forcing hospitals to defer non-urgent surgeries, and could hurt companies that make medical devic

Reuters - 1 month ago

Treace Files Patent Infringement And Unfair Competition Suit To Protect Lapiplasty Bunion Technology

BRIEF-Treace Files Patent Infringement And Unfair Competition Suit To Protect Lapiplasty Bunion Technology Oct 14 (Reuters) - Treace Medical Concepts Inc TMCI.O : TREACE FILES PATENT INFRINGEMENT AND UNFAIR COMPETITION SUIT TO PROTECT LAPIPLASTY® BUNION TECHNOLOGY TREACE MEDICAL CONCEPTS INC - FILES LAWSUIT AGAINST STRYKER AND ITS SUBSIDIARY WRIG

Reuters - 2 months ago

Stryker Completes Acquisition Of Nico Corporation

BRIEF-Stryker Completes Acquisition Of Nico Corporation Sept 20 (Reuters) - Stryker Corp SYK.N : STRYKER COMPLETES ACQUISITION OF NICO CORPORATION, EXPANDING MINIMALLY INVASIVE SOLUTIONS FOR BRAIN TUMOR REMOVAL AND STROKE CARE Source text for Eikon: ID:nPnSMmzca Further company coverage: SYK.N

Reuters - 3 months ago

Stryker Files For Offering Of € Denominated Notes, Size Not Disclosed - Filing

BRIEF-Stryker Files For Offering Of € Denominated Notes, Size Not Disclosed - Filing Sept 4 (Reuters) - Stryker Corp SYK.N : STRYKER FILES FOR OFFERING OF € DENOMINATED NOTES, SIZE NOT DISCLOSED - FILING Source text for Eikon: [ID:n0001193125-24-212577] Further company coverage: SYK.N

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.